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1. Introduction
Brain tumor surgery during pregnancy has a great concern in Egypt now days. High preva‐
lence of brain tumors during pregnancy y was noticed. There is no accurate statics for the
prevalence. The most common tumors are pituitary tumors, menegioma, gliomas, metastis of
breast carcinomas. Many problems affects anesthesia, as the interaction between many differ‐
ent factors, as the physiological changes during pregnancy, including, cardiovascular, respi‐
ratory changes [1]. Problems occur, during diagnosis, and treatment of tumors. Also problems
during surgery are, drug interactions with the anesthesia drugs, blood loss and transfusion,
prevention preterm labour, and anesthesia for urgent cesarean section during surgery for re‐
moval of brain tumor, in the chapter I tried to summary all these factors from anesthesia point
of views did many cases for brain resection during pregnancy,I hope to give this experience
for any young anesthesit how may facing such cases
1.1. Common tumors during pregnancy
1.1.1. Meningiomas
The incidence of meningiomas is approximately twice as high in women as in men. Specifically,
intracranial meningiomas are twice as common and intraspinal meningiomas nine times as
common in females [2]. Meningiomas also seem to have a relationship to sex hormones with
accelerated growth of these tumors during the luteal phase of the menstrual cycle and during
pregnancy [3]. There may also be an increased incidence of meningiomas in women with breast
cancer, although one study contests this relationship. A large number of studies have examined
the role of androgen, estrogen and progesterone receptors in meningiomas with most finding
progesterone and androgen receptors in a high proportion and low levels of estrogen receptors
© 2013 Goma; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
in a small proportion of meningioma specimens obtained at the time of initial surgery and at
recurrence [4].
1.1.2. Pituitary tumors
Pituitary tumors account for approximately 15% of all primary intracranial neoplasms and
occur in higher frequency in women, mainly in the child-bearing years [4].
The female preponderance of these tumors is due to the increased frequency of prolactinomas
in women in the second and third decades. Women are affected four times as commonly as
men and account for 78% of all prolactinomas [5].
1.2. Cranial metastases
1.2.1. Breast cancer
Breast cancer is the most common malignancy among women in North America accounting
for 27% of all cancers. Approximately 181,000 new cases of breast cancer were diagnosed in
1992 and 46,000 women died from the disease the same year. Neurologic complications occur
in approximately 25% of patients with metastatic breast cancer although autopsy studies have
demonstrated central nervous system involvement in 31-57% of examinations [6,7].
2. Problems in management of brain tumors with pregnancy
2.1. Problems in diagnosis
Symptoms of increased intracranial pressure including headache, nausea and vomiting are
similar to the symptoms of early pregnancy, or pregnancy related hypertensive diseas‐
es(eclampsia or preeclampsia ).
The use of Neuro imaging of the pregnant patient with these symptoms become necessary. In
the first trimester it is preferred to be avoided.the MRI is the procedure of choice as there is no
exposure to ionizing radiation. Although there is no evidence that MRI affects the fetus there
is exposure to powerful electromagnetic fields and this imaging modality should be avoided
if possible in the first trimester.Similarly, there is very little evidence regarding the safety of
the ferromagnetic contrast agent gadolinium and this is not sanctioned for use in pregnancy
and should be avoided if possible. In the patient with rapid neurologic deterioration compu‐
terized tomography (CT) may be necessary. This does involve radiation exposure of approx‐
imately 2.5 to 3 rads to the head of the patient and a fetal exposure estimated to be
approximately 1 mrad or less per slice which can be reduced by appropriate shielding of the
uterus with a lead apron. [9] At fetal exposures less than 10 rads no adverse effects in excess
of the background rate of spontaneous abnormalities in 3% of livebirths and the spontaneous
abortion rate of 30% in all pregnancies. Medically indicated exposures of up to 5 rads are
considered acceptable in pregnancy when unavoidable. There has been limited experience
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with the use of iodinated contrast agents during pregnancy and the risks are not precisely
defined. Such agents should be avoided in the first trimester.
2.2. Problems during treatment
Treatment of brain tumors or their complications may be necessary during pregnancy. Cere‐
bral edema and increased intracranial pressure may require the use of glucocorticoids and
mannitol. Glucocorticoids have been used during pregnancy for other reasons including the
prevention of neonatal respiratory distress syndrome and there is no evidence of growth,
physical, motor or developmental deficiencies within the first three years of life. However,
fetal adrenal suppression may occur with long-term, high dose therapy during any part of
pregnancy and necessitates the use of supplemental steroids in the peri-partum period. Al‐
though mannitol does cross the placenta and is excreted by the fetal kidney into the amniotic
fluid no adverse effects have been reported [10].
Cranial irradiation exposes the fetus to higher doses of radiation than diagnostic imaging. In
general, radiation exposure in utero carries a risk of adverse fetal outcomes including spon‐
taneous abortion, anatomic malformation, growth and mental retardation and possibly child‐
hood cancer with the latter risk highest in the first trimester The exposure to the fetus from
scatter is low when conventional radiation therapy is delivered to parts distant from the uterus
and such exposure carries low risk. Strategies to reduce fetal exposure include the use of focal
rather than whole brain irradiation, radiation dose reduction, substitution of heavy charged
particles for photons and deferring radiation until after delivery [11].
Chemotherapy typically involves agents which are teratogenic in the first trimester and asso‐
ciated with adverse fetal outcomes. Properties of chemotherapeutic agents which improve
permeability across the blood brain barrier also facilitate transport across the placenta making
these drugs especially hazardous. Although there is data to suggest that certain chemothera‐
peutic agents are associated with minimal risk in the second and third trimesters, chemother‐
apy for malignant brain tumors should be avoided during pregnancy. Meningiomas are
tumors that are thought to arise from meningothelial cells which make up the arachnoid villi
of the meninges. These lesions account for approximately 20% of all intracranial and 25% of
all intraspinal tumors and the incidence increases with age [11].
2.3. Problems during anesthesia for brain tumor surgery
Altered maternal physiology.
Respiratory system and acid-base balance changes
a. Alveolar ventilation increases 25% by the fourth month of gestation and 45% to 70% by
term. This results in a chronic respiratory alkalosis, with a Paco2 of 28 to 32 mm Hg, a
slightly alkaline pH (e.g., approximately 7.44), and decreased levels of bicarbonate and
buffer base.
b. oxygen consumption increases during gestation, Pao2 usually increases slightly or re‐
mains within the normal range.
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c. Functional residual capacity (FRC) decreases by approximately 20% as the uterus ex‐
pands, which results in decreased oxygen reserve and the potential for airway closure.
d. obesity; perioperative intraabdominal distention; placement of the patient in the supine,
Trendelenburg, or lithotomy positions), airway closure may be sufficient to cause hypo‐
xemia
e. Failed intubation (which is the leading cause of maternal death from anesthesia) is as much
a risk during nonobstetric surgery as it is during cesarean section.
f. rapid development of hypoxemia and acidosis during periods of hypoventilation or apnea
due to decreased FRC, increased oxygen consumption, and diminished buffering capaci‐
ty.
g. induction of general anesthesia occurs more rapidly during pregnancy, because alveolar
hyperventilation and a decreased FRC allow faster equilibration of inhaled agents.
h. Acceleration in the induction of anesthesia is the approximately 30% decrease in the min‐
imum alveolar concentration (MAC) for volatile anesthetic agents that occurs even during
early gestation.
Cardiovascular system changes
a. Cardiac output increases by 30% to 50% during pregnancy because of increases in heart
rate and stroke volume; both systemic and pulmonary vascular resistance decrease.
b. By eight weeks' gestation, 57% of the increase in cardiac output, 78% of the increase in
stroke volume, and 90% of the decrease in systemic vascular resistance that typically are
achieved by 24 weeks' gestation.
c. During the second half of gestation, the weight of the uterus compresses the inferior vena
cava when the mother lies supine; this decreases venous return and cardiac output by
approximately 25% to 30%.
d. Although upper extremity blood pressure may be maintained by compensatory vasocon‐
striction and tachycardia, uteroplacental perfusion is jeopardized whenever the mother
lies supine.
e. Frank hypotension also can occur in the supine parturient, especially when regional or
general anesthesia attenuates or abolishes normal compensatory mechanisms. is essential
to displace the uterus laterally during any operation performed after the twentieth week
of pregnancy.
Factors that can alter uteroplacental blood flow
1. Uterine Contraction
2. Decreased Uterine Blood Flow
3. Pathological Conditions
4. Pharmacological Agents
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Intravenous induction agents
5. Inhalation agents (Desflurane and sevoflurane)
6. Antihypertensive agents
7. b-adrenergic blocking drugs
8. Tocolytic drugs
9. Epidural and subarachnoid opiates
10. Local anesthetics
11. Pharmacological agent added to the local anesthetic
12. Vasopressors
Maintenance of uteroplacental blood flow is the hallmark for fetal well-being; hence an in-
depth knowledge of this subjectis essential for individuals taking care of pregnant women.
Uterine blood flow is determined by the equation.Hence any condition that will significantly
decrease mean [14,15]
Uterine arterial pressure – Uterine venous pressure
Uterine vascular resistance (1)
So  when  maternal  arterial  pressure  decreases  or  significantly  increase  uterine  vascular
resistance  will  decrease  utero  placental  blood  flow  and,  ultimately,  umbilical  blood
flow.At term, 10% of the cardiac output (700 mL/min) supplies the uterus. The placental
vasculature remains maximally [16,17,18].
Changes in blood volume and blood constituents
• Blood volume expands in the first trimester and increases 30% to 45% by term. A smaller
increase in red blood cell volume than in plasma volume results in a dilutional anemia.
• moderate blood loss is well tolerated during pregnancy, preexisting anemia decreases the
patient's reserve when significant hemorrhage occurs. Fresh blood transfusion is needed to
compensate blood loss during brain tumor surgery [18].
• Pregnancy induces a hypercoagulable state, with increases in fibrinogen; factors VII, VIII,
X, and XII; and fibrin degradation products. Pregnancy is associated with enhanced platelet
turnover, clotting, and fibrinolysis, and there is a wide range in the normal platelet count;
thus pregnancy represents a state of accelerated but compensated intravascular coagulation.
During the postoperative period, pregnant surgical patients are at high risk for throm‐
boembolic complications.
• It is great challenge to Induce hypotensive technique and to maintain the placental perfusion
pressure [19].
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Gastrointestinal system changes
• Incompetence of the lower esophageal sphincter and distortion of gastric and pyloric anat‐
omy result in an increased risk of esophageal reflux and aspiration pneumonitis.
• It seems prudent to consider any pregnant patient at risk for aspiration after 18 to 20 weeks'
gestation.
• Rapid sequence induction to avoid aspiration and deep anesthesia to prevent increase in
the intracranial pressure during brain tumor surgery is another problem.
• preoperative antiacid,sodium citreate, meteclopramid,muscle relaxant as rocuronium.
• complete recovery is needed before extubation.
Altered Responses to Anesthesia
• The decrease in MAC for inhaled anesthetic agents,
• thiopental requirements begin to decrease early in pregnancy.
• Plasma cholinesterase levels decrease by approximately 25% from early in pregnancy until
the seventh postpartum day. Cautions in use of remifentanil and succinylcholine.
• The anesthesiologist should monitor neuromuscular blockade with a nerve stimulator to ensure
adequate reversal before extubation.
• Decreased protein binding associated with low albumin concentrations during pregnancy
may result in a greater fraction of unbound drug, with the potential for greater drug toxicity
during pregnancy.
• Antiepileptic drugs as Carbamazepine and, Phenytoin may potentiate effects of anesthestic
drug used [20,21,22].
Risk of teratogenicity
• Teratogenicity has been defined as any significant postnatal change in function or form in an
offspring after prenatal treatment. Concern about the potential harmful effects of anesthetic
agents stems from their known effects on mammalian cells. These occur at clinical concen‐
trations and include reversible decreases in cell motility, prolongation of DNA synthesis,
and inhibition of cell division.Despite these theoretical concerns, no data specifically link
any of these cellular events with teratogenic changes.
Anticonvulsants
• All anticonvulsants cross the placenta. Pregnant women with epilepsy who ingest anticon‐
vulsant drugs have a fetal congenital anomaly rate of 4% to 8%, which is higher than the 2%
to 3% background incidence quoted for the general population.
• Carbamazepine
• Phenobarbital is used in the treatment of partial and generalized tonic-clonic seizures and
status epilepticus
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• Valproic acid (Depakene, Depakote) is used to treat absence and generalized tonic-clonic
seizures [23,24,25].
Tranquilizers
Some studies have suggested that first-trimester exposure to diazepam increases the risk of
cleft lip.
Lithium
In the International Registry of Lithium Babies, (11.5%) of 217 infants exposed to lithium
during the first trimester of pregnancy were malformed.Eighteen infants had cardiovascu‐
lar anomalies.
Antidepressants
The selective serotonin reuptake inhibitors include sertraline (Zoloft), paroxetine (Paxil),
fluoxetine (Prozac), and citalopram (Celexa). No increased risk of major malformations or
developmental (language and behavior) abnormalities has been identified.
Nitrous oxide
In vivo and embryo culture studies in rats have confirmed that nitrous oxide produces several
adverse reproductive effects, each of which results from exposure at a specific period of sus‐
ceptibility [21].
Use  of  electronic  fetal  monitoring  for  assessing  fetal  well-being  has  become  universal,
used by both physicians and nurses. Monitoring the fetal heart rate is used to determine
adequate cerebral oxygenation of the fetus. As the brain modulates the heart, a decrease
in fetal heart rate is believed to reflect inadequate fetal cerebral oxygenation.External fetal
heart  ratemonitors  use  a  Doppler  detective  device  with  computerized  logic  to  inter‐
pret,and  count  the  Doppler  signals,whereas  internal  fetal  heart  rate  monitors  involve
placement  of  an  electrodeon the  fetal  scalp.  The presenceof  fetal  heart  tones  as  well  as
their  rate  and rhythm are  well-recognized indicators  of  fetal  well-being.  A normal  fetal
heart rate tracing reveals a rate of 110–160 beats/min with minimal to moderate beat-to-
beat variability with or without accelerations. Apretermfetus is expected to have a more
rapid rate with little or no beat-to-beat variabilityand no accelerations (an increasein fetal
heart rate over baseline, usually occurring with fetal movement.
The goal of antepartum fetal surveillance is to document fetal wellbeing,allowing the preg‐
nancy to continue without concern for fetal death.Several antepartum techniques in use in‐
clude fetal movement, nonstress test, contraction stress test, biophysical profile, and umbilical
artery Dopplerflow velocimetry [26,27,,28,29,30]
Prevention of preterm labor
Fetal movement is the easiest means for documenting fetal well-being. The mother can perceive
fetal movements,which serve as a basis for assessment.A diminution in the perception of fetal
movement often precedes fetal death. Perception of 10 distinct movements in a period of up
to 2 hours is considered reassuring. Heart rate reactivity is thought to be a good indicator of
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normal fetal autonomic function. Loss of reactivity is associated most commonly with fetal
sleep but also may result from any central nervous system depression. A nonstress test involves
connecting themother to the fetal heart rate monitor and observing. Non stress test results can
be categorized as reactive or nonreactive.
The non stress test is considered reactive (normal) if two or more fetal heart rate accelerations
are observed within a 20-minute period. The non stress test is considered nonreactive when no
accelerations are observed [32,33]
Guidelines for the management of preterm delivery.
• Confirm diagnosis of preterm labor
• Exclude contraindications to expectant management and/or tocolysis
• Administer corticosteroids, if indicated
• Group B Streptococcus chemoprophylaxis, if indicated
• Pharmacologic tocolysis
• Consider transfer to tertiary care center
There is increased incidence of abortion and preterm delivery. volatile halogenated agents
depress myometrial irritability The prophylactic use of tocolytic agents is controversial; they
are not without risk, and it is unclear whether they affect outcome. Selective administration to
those patients at greatest risk (e.g., those undergoing cervical cerclage) has been suggested
[34,35].
Anesthetic management
1. Unlike other operations wherein thepatient is primarily concerned with him or herself,
the pregnant woman usually is concerned for her baby’swelfare.
2. The anesthesia provider must beaware of the various physiologic changes of pregnancy
and incorporatethem into the anesthetic plan.
3. These physiologic changes have implications for various diseases and must be considered.
4. The central nervous system effect of pregnancy include a reduced local anesthetic re‐
quirement when these agents are given intrathecally or epidurally.
5. Pregnant patients are at increased risk for aspiration during general anesthesia.
6. There is some suggestion that surgery during the first trimester is linked to central nervous
defectsduring surgery.
7. Fetal heart rate monitoring is possible during some surgical procedures but is not uni‐
versally used in theUnited States.
8. Preterm delivery remains the leading cause of perinatal morbidity and mortality in the
United States. Preterm labor is difficult to control with medication; the most promising
medications are the calcium channel-blocking drugs. Magnesium sulfate is frequently
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used and is associated with prolonged depolarizing and nondepolarizing neuromuscu‐
larblockade.
9. The etiology of preeclampsia remains to be elucidated but is believedto be triggered by a
paternal antigen in a susceptible mother.
10. Magnesium sulfate is the most effective medication for the prevention of seizures in
women with preeclampsia.
11. Labetalol is the preferred medicationfor the control of blood pressure in mothers with
preeclampsia.
12. The two causes of antepartum hemorrhage are placenta previa and placental abruption.
Associated with the increase in cesarean sections isa high risk of placenta accreta in pa‐
tients with placenta previa.
13. Perinatal transmission of HIV is low if the viral load is <1,000 copies/mL, and patients
with these levels do not require cesarean section. If theviral load is greater, cesarean sec‐
tion may decrease the risk of perinatal transmission [36,37].
3. Preoperative management
Premedication may be necessary to allay maternal anxiety. Precautions against acid aspiration
should include administration of an H2-receptor antagonist and 30 mL of a clear antacid before
the induction of anesthesia.
4. Choice of anesthesia
The choice of anesthesia should be guided by maternal indications and should take into con‐
sideration the site and the nature of the surgery. No study has correlated improved fetal out‐
come with any anesthetic technique. When possible, local or regional anesthesia (with the
exception of paracervical block) is preferred; this permits the administration of drugs with no
laboratory or clinical evidence of teratogenesis. In addition, maternal respiratory complica‐
tions occur less frequently with local and regional anesthetic techniques. These techniques are
suitable for cases involving cervical cerclage, urologic or lower extremity procedures, and
operations on the arm or hand. Most abdominal operations require general anesthesia, because
the incision typically extends to the upper abdomen, which creates an unacceptable risk of
aspiration in a pregnant patient with an unprotected airway [38,39].
5. Prevention of aortocaval compression
Beginning at 18 to 20 weeks' gestation, the pregnant patient should be transported on her side,
and the uterus should be displaced leftward when she is positioned on the operating table.
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6. Monitoring
Maternal monitoring should include noninvasive or direct blood pressure measurement, elec‐
trocardiography, pulse oximetry, capnography, temperature monitoring, and the use of a
nerve stimulator. The FHR and uterine activity should be monitored both during and after
surgery when technically feasible.
7. Anesthetic technique
General anesthesia mandates endotracheal intubation beginning at approximately 18 to 20
weeks' gestation or earlier if gastrointestinal function is abnormal. Denitrogenation (i.e., pre‐
oxygenation) should precede the application of cricoid pressure, rapid-sequence induction,
and endotracheal intubation. Drugs with a history of safe use during pregnancy include thi‐
opental, morphine, meperidine, fentanyl, succinylcholine, and most of the nondepolarizing
muscle relaxants. Many obstetric anesthesiologists would now add propofol to the list of “safe”
drugs for use during pregnancy.
A commonly used technique employs a high concentration of oxygen, a muscle relaxant, and
an opioid and/or a moderate concentration of a volatile halogenated agent. Scientific evidence
does not support avoiding nitrous oxide during pregnancy, particularly after the sixth week
of gestation. Omission of nitrous oxide may increase fetal risk if inadequate anesthesia results
or if a high dose of a volatile agent results in maternal hypotension. A cautious approach would
restrict nitrous oxide administration to a concentration of 50% or less and would limit its use
in extremely long operations. Hyperventilation should be avoided; rather, end-tidal CO2
should be maintained in the normal range for pregnancy.
Before the administration of spinal or epidural anesthesia, rapid intravenous infusion of 1 L
of crystalloid seems prudent, although the anesthesiologist should not assume that this will
prevent maternal hypotension. Appropriate vasopressors should be available to treat hypo‐
tension if it occurs. The usual precautions must be taken to guard against a high block and
systemic local anesthetic toxicity.
Regardless of the technique used, avoidance of hypoxemia, hypotension, acidosis, and hyper‐
ventilation are the most critical elements of anesthetic management.
8. Postoperative management
8.1. Postoperative management
The FHR and uterine activity should be monitored during recovery from anesthesia. Adequate
analgesia should be obtained with systemic or spinal opioids. Prophylaxis against venous
thrombosis should be considered [38,39,40,41].
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Case study:
• Pregnant woman 30 weeks of pregnancy, she was complained from multiple menegiomas,
conservative treatment was used throughout pregnancy period. this patient developed sev‐
er continuous vomiting,and rapid deterioration of nutritional status,neuro surgery team
decided urgent operation for decompression of the brain, the patient was referred for ob‐
stetric,and anesthesia consultant.
• Anesthesia examination revealed that :
Patient 35 years old 65 Kg, this the first baby,she complained from infertility for 15 years,she
was hypertensive 150/90 on aldomit.anticovasant drugs was admintsred,liver enzymes was 2
folds,albumen was 2,5, prothrombin was 65% kidney function within normal range. Hb was
6,5gm/dl, Obesteric examination revealed that baby nearly mature,his weigt is under weight.
• Preoperative preparation:
Anesthesia consultant recommended blood transfusion for 4 units of packed RBCs,4 units of
human albumen, 4 units of fresh plasma 2 days before surgery. Preparations of another for
units of fresh blood were for intraoperative losses Preoperative antacid was administered.
Obstetric Preparations was for urgent cesarean section. Pediatric preparing to receive the pre‐
mature neonate if urgent cesarean section was needed
• Anesthesia management:
• Monitoring:
Invasive blood pressure, ECG,endtidal CO2,pulse oximetry, uterine contraction monitor, fetal
Doppler. Postioning: Supine with left lateral tilt,
8.2. Induction of anesthesia
3-5 mg/kg sodium thiopental, rocuronium 04 meg/kg, fentanyl 1mg/kg. Intubation by rapid
sequence, the precautions mentioned above were considered
The operation was long 5 hours, blood loss was replaced, fetal heart was declined at third
hour,urgent cesarean section was done,the pediatric consultant intubated the neonate,and he
was incubated,for 2 weeks,he extubated and he is still living.mother was in intensive care unit
for 3 days.
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